Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Providing a written informed consent (see Appendix A);~* Age ≥18 years;~* Histologic or cytologic confirmed diagnosis of NSCLC of any epithelial type (squamous, adenocarcinoma, large cell, or other);~* At least one newly diagnosed measurable metastatic lesion from NSCLC in the brain;~* Patient had initial diagnosis of brain metastases by image, within 8 weeks of registration~* KPS ≥70;~* Absolute neutrophil count ≥ 1500/mm³;~* Platelet count ≥ 50,000/mm³;~* Serum creatinine ≤2.0 mg/dL;~* Serum transaminases ≤2 x the upper limit of normal (ULN);~* Total serum bilirubin ≤2 x ULN;~* And a lactate dehydrogenase (LDH) level ≤1.3 x ULN.~Exclusion Criteria:~* Pregnancy, lactation or parturition within the previous 30 days (fertile female or male patients should practice contraception);~* Prior WBRT, brain metastases resection with no other measurable lesion remaining;~* Extracranial metastases in two or more organs;~* Known leptomeningeal or subarachnoid tumor spread;~* Plan to use radiosurgery or radiation boost after completion of WBRT;~* Plan to use chemotherapy or any other systemic antineoplastic modality during WBRT;~* Previous use of an anti-EGFR drug;~* Participation in another ongoing therapeutic trial;~* Presence of known HIV seropositivity, severe comorbidities, or other malignant neoplasm within 5 years (except adequately treated basal- or squamous-cell carcinoma of skin or in situ carcinoma of the uterine cervix);~* Hypersensitivity or allergy to any of the drugs to be administered in this study;~* Inability or unwillingness to complete the required assessments;~* Geographic inaccessibility for treatment or follow-up evaluations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT. Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
- 2 (Type: PLACEBO_COMPARATOR): A placebo will be administered by the intravenous route weekly during WBRT and following WBRT.~Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).